Background
Sarcoidosis is a multisystem, granulomatous disease seen worldwide, with a prevalence of 4.7 -64 in 100 000; reported rates are highest in individuals of northern European and AfricanAmerican descent, especially women. 1, 2 The aetiology of sarcoidosis is unknown, but there is growing evidence to suggest an immunological response to an unidentified antigenic trigger in individuals with genetic susceptibility. 3 More than 90% of patients will have lung involvement; the disease can also affect the skin, eyes, liver, heart, parotid gland, spleen, and other tissues and organs. Most disease occurs in patients between 25 and 60 years of age 1, 2 and sarcoidosis is unusual in people under the age of 15 or older than 70. 3 Approximately 5% of patients with sarcoidosis have clinically manifest cardiac involvement. Clinical features of cardiac sarcoidosis (CS) are dependent on the location, extent, and activity of the disease. Furthermore, the cardiac symptoms are usually dominant over extra-cardiac as most patients with clinically manifest CS have minimal extra-cardiac disease and up to two-thirds have isolated CS. 4 -8 Indeed, both presentation and subsequent course with clinically isolated cardiac involvement is possible. 4, 8 Another 20 -25% of patients have asymptomatic (i.e. clinically silent) cardiac involvement. This latter finding was established initially from autopsy studies that estimated the prevalence of cardiac involvement. 9 These data are aligned with recent data using late gadolinium (LGE)-enhanced cardiac magnetic resonance technology. Studies suggest an increasing prevalence of CS; however, this is most likely the result of enhanced imaging technology and/or more in-depth investigation. For example in the USA, the incidence of patients with CS as the aetiology of cardiomyopathy, who underwent transplantation, rose to 0.5% (between 2010 and 2014) from 0.1% (between 1994 and 1997). 10 Similarly, in Finland, CS was diagnosed at a rate that increased .50-fold between 1988 and 2014. 8 In addition, there is mounting awareness that CS can be the earliest indicator of sarcoidosis in any organ. 5, 6, 11, 12 Diagnosis of cardiac sarcoidosis Echocardiography Abnormalities tend to be non-specific and variable; interventricular thinning (particularly basal) is the most typical feature of CS. Less commonly an increase in myocardial wall thickness may be seen, simulating left ventricular (LV) hypertrophy or hypertrophic cardiomyopathy. 13 There may be other abnormalities, such as aneurysms, LV and/or right ventricular (RV) diastolic and systolic dysfunction, and isolated wall motion abnormalities. Usually, regional wall motion abnormalities appear in a non-coronary distribution.
Cardiac magnetic resonance imaging
No specific pattern of LGE is diagnostic for CS, although typically it is multi-focal and patchy, with sparing of the endocardial border.
14 Late gadolinium enhancement is most often seen in basal segments (particularly of the septum and lateral wall) and typically in the epicardium and mid myocardium, 15, 16 although subendocardial coronary artery disease-like pattern is also possible. 17 Transmural involvement can occur, however, and in some cases, there may also be involvement of the RV-free wall. 17 
Fluorodeoxyglucose Positron Emission Tomography imaging
A glucose analogue, fluorodeoxyglucose (FDG), is useful in distinguishing inflammatory lesions, in which the activated pro-inflammatory macrophages show a higher metabolic rate and glucose utilization. 18 No individual clinical finding is pathognomonic for the diagnosis, but focal or focal-on-diffuse FDG uptake patterns suggest active CS. 19, 20 There have been suggestions that PET could be a useful disease activity marker for guiding CS therapy. Figure 1 shows Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) imaging before and after treatment. Of note, FDG-PET testing should only be performed at centres that have experience in CS imaging protocols. 21 A key factor in optimizing diagnostic accuracy is the suppression of physiological FDG uptake in the cardiac muscle. 22 A variety of preparation protocols have been used; usually with prolonged fasting of at least 12 h with fatty rich and low carbohydrate meals the day before. Inadequate preparation can lead to false-positive FDG-PET scans. 22 North American guidelines are currently being developed and the Japanese Society of Nuclear and European Medicine published a consensus guideline in 2014. 22 Quantification of myocardial perfusion combined with FDG imaging may add prognostic value. 23 To evaluate extra-cardiac involvement and to help finding biopsy targets in suspected CS, it is useful to always acquire whole body FDG-PET images in addition to the cardiac study. 7 There is now technology to support fused PET/CMR, which enables concurrent imaging of the two disease stages, inflammation and fibrosis/scar. 24 
Biomarkers
Historical sarcoidosis biomarkers, circulating ACE and lysozyme, are frequently measured in suspected CS, but their utility is limited. 3 For this reason, studies have focused on searching for new biomarkers to evaluate disease activity; researchers have observed significantly elevated levels of neopterin and especially soluble interleukin-2 receptor levels in patients with active disease. 25 In 2015, Kandolin et al. measured
highly sensitive Troponin levels in 62 patients with new-onset CS. Thirty-three patients showed elevated concentrations at presentation; in 67% of cases, these normalized after steroid use for 4 weeks. 26 
Tissue biopsy
In most centres, lymph node or lung biopsy is targeted first in patients with extra-cardiac sarcoidosis because of the lower procedural risk and higher diagnostic yield. In negative extra-cardiac biopsy cases and in patients having no extra-cardiac disease either clinically or at whole body FDG-PET, endomyocardial biopsy (EMB) is necessary to confirm the diagnosis. However, EMB has Cardiac manifestations of sarcoidosis low sensitivity due to the disease's focal nature. 27 To increase the procedure's sensitivity, electrophysiological (electro-anatomic mapping, see Figure 2 ) 28,29 or imaging (PET or CMR) 4 -guided biopsy procedures have been described, and are now recommended by consensus guidelines. 21 Positive biopsy rates have risen to 50% due to these techniques. 4, 7, 29 Consensus guidelines for diagnosing cardiac sarcoidosis
The first international expert consensus statement for CS diagnosis was published in 2014 (see Table 1 ) by experts chosen by the Heart Rhythm Society in collaboration with multiple other societies. 21 Until this statement was released, the only published diagnostic guidelines were the criteria from the National Institutes of Health's A Case Control Etiology of Sarcoidosis Study 30 and the Japanese Ministry of Health and Welfare criteria. 31 It should be noted that none of these diagnostic criteria have been prospectively validated.
Screening for cardiac sarcoidosis Screening for cardiac involvement in patients with biopsy proven, extra-cardiac sarcoidosis
There are scarce data to compare the specificity and sensitivity of screening tests for cardiac involvement in patients with extracardiac sarcoidosis. Mehta et al. 32 screened 62 extra-cardiac sarcoidosis patients with echocardiography, detailed cardiac history, Holter monitoring, and ECG and reported a specificity of 87% and a sensitivity of 100% for the diagnosis of CS if any of the screening variables was positive. 32 It is apparent that larger studies are needed to define the sensitivity and specificity (and cost effectiveness) of various screening strategies and tests to detect clinically silent cardiac involvement. This need pertains to possible screening with CMR in particular. As well, there are no data regarding whether or not interval rescreening is required.
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Cardiac sarcoidosis screening in patients with specific cardiac presentations
Cardiac presentations can be the first manifestation of sarcoidosis in a variety of circumstances.
Unexplained Mobitz II or third degree atrioventricular block in young patients
In a Finnish study of 72 patients aged ,55 with new-onset, unexplained, significant conduction system disease, biopsy-verified CS was found in 14/72 (19%); 'probable' CS was found in 4/72 (6%); and giant cell myocarditis was found in 4/72 (6%). The prognosis for CS patients was poorer vs. those who had idiopathic complete AV block. 11 In a similar study from a tertiary Canadian centre, CS was diagnosed in 11/32 (34%) patients aged ,60.
6
Sustained monomorphic ventricular tachycardia of unknown aetiology
In a prospective study that screened consecutive patients with VT of unknown aetiology for sarcoidosis, 4 of 14 patients (29%) were diagnosed with CS. 5 In a study by Tung of 103 patients (85% Caucasian, 7% African-American, and 8% Asian) with VT and nonischaemic cardiomyopathy, 17/103 (16.5%) had undiagnosed CS.
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Arrhythmogenic right ventricular cardiomyopathy 
Idiopathic heart failure
Cardiac sarcoidosis is frequently overlooked as the underlying cause of heart failure. Core LV biopsies during LV assist device implantation identified previously undiagnosed CS in 6 of 177 mixed cardiomyopathy patients (3.4%). 34 Examination of explanted hearts found that among 130 heart transplants with a clinical diagnosis of nonischaemic cardiomyopathy, 8 (6.2%) had undiagnosed CS. 35 
Clinical management Role of immunosuppression
A systematic review of corticosteroids for the treatment of CS was published by Sadek et al. 36 Ten manuscripts met the criteria for inclusion. There were no randomized trials and all publications ranged from poor to fair in quality. The highest quality data related to AV block and LV dysfunction; because of limitations in data quality, no clear conclusions could be established for other outcomes. 36 Twenty-seven of 57 patients (47.4%) treated with corticosteroids had improvements in AV conduction while in contrast, out of 16 patients not treated with corticosteroids, 0/16 improved. 36 The data summary for LV dysfunction from 73 patients, of whom 60 were treated with steroids and 13 were not, suggested that corticosteroid therapy is associated with maintenance of LV function in patients who have normal function at diagnosis, with improved ejection fraction in those with mild-tomoderate LV dysfunction and no improvement was found in patients with severe LV dysfunction. 36 In contrast, a more recent study of 102 CS patients showed improved LV function after steroid therapy in patients with severely depressed ejection fraction (,35%) but no change in patients with moderately depressed ejection fraction. 8 Most experts have been proponents of treating CS despite this scarcity of data. It is not clear whether it is best to treat all CS patients, or only those with clinically manifest disease with evidence of ongoing myocardial inflammation. Other unknowns include the optimal doses of corticosteroids and the best techniques for assessing response to treatment; most experts recommend a starting dose of 30-40 mg daily. 37 Response to treatment should be evaluated after 1-3 months and the dosage adjusted as needed: i.e. if there has been a response, the prednisone should be gradually reduced to between 5 and 15 mg/ day, with a view to continuing treatment for a total of 9-12 more months. 37 Due to the possibility of relapse, physicians should follow patients for minimum 3 years after completing treatment. 3 In refractory cases or in if significant steroid side effects develop, methotrexate is commonly used as a second line drug. 38 Azathioprine, cyclophosphamide, and infliximab are also sometimes used to treat CS. 39 
Management of left ventricular dysfunction
Patients who have CS and LV dysfunction should also be treated with standard medical and device therapies for heart failure, including heart transplantation. Recurrent disease has been reported in the transplanted heart but long-term patient outcomes are similar to outcomes for control groups. 40 
Conduction abnormalities
Implantable cardioverter defibrillator implantation is generally recommended for patients with an indication for pacing as these patients have a substantial risk of VTVF in follow-up. 41 See Table 2 for a summary of the recent consensus document. 
Ventricular arrhythmias
Macro re-entrant arrhythmias around areas of granulomatous scar are the most common mechanism of ventricular arrhythmia. 42, 43 It is believed that active inflammation may contribute to monomorphic ventricular tachycardia due to re-entry by triggering it with ventricular ectopy or slowing conduction in diseased tissue within granulomatous scar. Corticosteroids are commonly used despite minimal data to support their use. 36 Reflecting extensive scarring and multiple inducible morphologies, ablation outcomes are modest. In Kumar's study, the multiple procedure VT-free survival rate was 37% at 1 year. 43 Another study found a recurrence rate of 44%. 42 A stepwise approach, therefore, is recommended ( 
Prognosis
Generally, the prognosis for CS patients is less favourable than for those without cardiac involvement. In the current era of heart failure therapy, including active transplant surgery, deaths from heart failure have become rare and the majority of fatalities are due to ventricular arrhythmias. In a recent Finnish nationwide study, 10-year cardiac survival was 92.5% in 102 patients (see Figure 4) . 8 The extent of LV dysfunction is commonly regarded as the most important predictor of survival. 36 Several recent CMR studies have, however, raised the presence and extent of myocardial LGE as an even more important overall prognostic factor than LV function. 46, 47 Also recent findings have suggested that RV involvement on CMR 46, 47 or PET 23 may also have important predictive value.
There is some controversy in the literature as to the prognosis of patients with clinically silent CS. Many of the studies are limited by variable inclusion criteria, possible biases, and other potential methodological issues. Some studies found a benign course. 32, 48, 49 Conversely, three studies reported sharply contrasting findings. 17, 46, 50 Larger studies regarding the prognosis of patients with clinically silent CS are needed.
Conclusions and future directions
Approximately 5% of patients with sarcoidosis will have clinically manifest cardiac involvement and another 20 -25% have asymptomatic cardiac involvement (clinically silent disease). There is a growing understanding that CS can be the first manifestation of sarcoidosis in any organ. The extent of LV dysfunction seems to be the most important predictor of prognosis. In addition, the extent of LGE is emerging as an important prognostic factor. There is some controversy regarding outcomes for patients with clinically silent CS and larger studies are needed. Immunosuppression therapy (usually with corticosteroids) has been suggested for the treatment of clinically manifest CS despite modest data. Patients with clinically manifest disease often need device therapy, typically with implantable cardioverter defibrillators. There are still many unknowns in terms of best practices in diagnosing and managing CS patients and multi-centre research efforts are underway.
